Spots Global Cancer Trial Database for RNA-Loaded Dendritic Cell Cancer Vaccine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: RNA-Loaded Dendritic Cell Cancer Vaccine
Official Title: A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma
Study ID: NCT00087984
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of administering a dendritic cell vaccine to patients with metastatic renal cell carcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California - Irvine, Orange, California, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Princess Margaret Hospital, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
